Abstract: To enhance the quality and efficiency of ozagrel by investigating the differences between the ozagrel polymorphs in bioavailability. Solid ozagrel in different polymorph forms were orally administered to SD rats. An HPLC method was established to determinate plasma level of ozagrel. The bioavailabilities of two polymorph forms were calculated and compared. The pharmacokinetic parameters of ozagrel, were as follows: C_max was 32.72±17.04 and 34.01±19.13 mg·L^-1, respectively; AUC_0-t was 61.14±14.76 and 85.56±18.08 mg·L^-1•h, respectively; t_1/2 was 1.53±0.51 and 4.73±3.00 h, respectively. There was no significant difference in pharmacokinetic parameters between form Ⅰ and Ⅱ polymorphs of ozagrel while the t_1/2 of form Ⅱ is longer, which indicates that the use of form Ⅱ polymorph as pharmaceutical product may prolong the effective action time in clinics. This would help the polymorph quality control in drug production.